No Data
Jefferies Adjusts Astellas Pharma's Price Target to 1,500 Yen From 1,700 Yen, Keeps at Hold
No plans (21st) [Financial results schedule]
※ The above Calendar is just a schedule and may be subject to change due to company circumstances. --------------------------------------- April 21 (Monday) --------------------------------------- April 22 (Tuesday) <2268> Thirty-One <3091> Bronco B <4479> Makua-ke <4684> Obic <4733> OBC
Amgen Inc. (ADR) (ALPMY.US) will release its Earnings Reports after the market closes on April 24.
$Astellas Pharma (ADR)(ALPMY.US)$ will release its earnings reports after the market closes on April 24, and investors should pay attention. How were the previous results? $Astellas Pharma (ADR)(ALPMY.US)$ had revenue of 517.408 billion yen and a net income of -97.66 billion yen with an EPS of -54.55 yen for Q3 2025. For Q4 2024, the revenue was 414.602 billion yen, the net income was -33.278 billion yen, and the EPS was -18.55 yen. The accounting standards used for the above data are NonUS_GAAP. Futubull reminder.
Sumitomo Electric, Kobayashi Pharmaceutical ETC (Additional) Rating
Target Price Change Code Stock Name Securities Company Previously Changed After-----------------------------------------------<1928> Sekisui House City 4500 yen 3900 yen <2413> M3 GS 2300 yen 2150 yen <3116> Toyota Boshoku GS 2300 yen 2000 yen <3281> GLP Nomura 166000 yen 160000 yen <4151> Kyowa Kirin GS 2500 yen 2400 yen <4483> JMDG GS 47
Chromatin Bioscience Signs Collaboration Agreement With Astellas
Eli Lilly to Leverage Sangamo Capsid Technology for CNS Disease Therapies
